The A2 Milk Company is off to a FY19 flier, lifting its earnings for the first four months of the year while appearing unfazed by the prospect of higher marketing costs, and the impact of China's new cross-border e-commerce laws.

The expanding dairy and infant formula producer lifted net profit by 64.5 per cent to $NZ86 million ($80.62 million) between July and October while revenues rose 40.5 per cent to $NZ368.4 million.

Shares in A2 lifted by as much as 7 per cent in early trade, and were up 2.04 per cent to $10.00 at 11am Sydney time on Tuesday.

a2milk earnings report best ideas

The A2 Milk Company more than doubled its full-year profit in FY18

Chief executive Jayne Hrdlicka is sticking by the company's previous guidance for this financial year of more moderate revenue growth while underlying earnings are expected to be broadly in line with last year.

The New Zealand-based company's expansion into China and the US is set to increase A2's marketing costs, but its increasing share of the Australian fresh milk market, as well as further growth for its flagship A2 Platinum infant formula, is fuelling a positive outlook.

"We have a strong brand, special culture and unique proposition, the combination of which positions us very well for the future," Hrdlicka said in a speech to be delivered at Tuesday's annual general meeting in Melbourne.

"We are not concerned about the current regulatory dynamic in China and elsewhere in the world."

Hrdlicka said A2 and its daigou network had long been anticipating changes to China's domestic and cross-border e-commerce rules, and both were well prepared to adapt and grow with the new regime.

She said the company would also keep its eye on an increased consumer focus on health and wellness - in particular digestive health - and a growing focus on food safety, naturalness and the provenance of food.

The growing middle class in Asia and China was also key, she said.

The company more than doubled its full-year profit in FY18 to $NZ195.7 thanks to continued strong demand for its baby formula in Australia and China.

Morningstar last month elevated A2 to its list of global equity best ideas, citing the opportunities for growth in China, and setting a fair value estimate of $13.30

Morningstar director of equity research for Australia and New Zealand, applauded the result, saying it was largely in line with expectations.

"Overall, the key positives for me in management’s comments are that (a) the firm continues to gain share in China, despite new competition. This is in-line with our expectation for about 1 point of market share gain per year for the next 10 years," Fleck said.

"And (b) the new e-commerce regulations are not likely to be a long-term impediment to this success."

 

More from Morningstar

Investing not just for white-collar wealthy

Tick for media mergers spurs boost in Nine's fair value

Make better investment decisions with Morningstar Premium | Free 4-week trial

 

Morningstar with AAP

Lex Hall is content editor, Morningstar Australia

© 2018 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'class service' have been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/s/fsg.pdf. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782 ("ASXO"). The article is current as at date of publication.